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Abstract
Background and objectives: The vascular access pressure ratio test identifies dialysis vascular access dysfunction
when three consecutive vascular access pressure ratios are >0.55. We tested whether the magnitude of the decline in
vascular access pressure ratio 1-week post-intervention could alert of subsequent access failure.
Design, setting, participants, and measurements: The retrospective study included all vascular access procedures
at one institution from March 2014 to June 2016. Data included demographics, comorbidities, vascular access features,
%ΔVAPR = ((Pre-Post)/Pre] × 100% assessed within the first 2 weeks post-percutaneous transluminal balloon angioplasty,
time-to-next procedure, and patency. The log-rank test compared the area under the curve, receiver operating curve,
Kaplan–Meier arteriovenous graft and arteriovenous fistula survival curves. A multivariable Cox proportional hazard
(CP) model was used to determine the association of %ΔVAPR with access patency.
Results: Analysis of 138 subjects (females 51%; Black 87%) included 64 arteriovenous fistulas with 104 angioplasties
and 74 arteriovenous grafts with 134 angioplasties. The area under the receiver operating characteristic curve for
fistula failure at 3 months was 0.59, with optimal screening characteristics of 33.3%, sensitivity of 56.1%, and specificity
of 63.2%. Arteriovenous fistula with <33.3% decline compared to >33.3% required earlier subsequent procedure
(136 vs 231 days), lower survival on Kaplan–Meier analysis (P = 0.01), and twofold greater risk of failure (P = .006). Area
under the receiver operating characteristic for arteriovenous graft failure at 3 months had a sensitivity of 52.3% and
specificity of 67.4%. Arteriovenous graft with a post-intervention vascular access pressure ratio decline of <28.8% also
required earlier subsequent procedure (144 vs 189 days), lower survival on Kaplan–Meier (P = 0.04), and a 59% higher
risk for failure. The area under the receiver operating characteristic curve for combined access failure (arteriovenous
fistula + arteriovenous graft) at 3 months had an optimal cut-point value of 31.2%, a sensitivity of 54.6%, and a specificity
of 63.1%. Access with a <31.2% drop had a 62% increase in the risk of failure (hazard ratio 1.62; confidence interval
1.16, 2.27; P = 0.005).
Conclusion: The magnitude of post-intervention reduction in vascular access pressure ratio provides a novel predictive
measure of access outcomes.
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Arteriovenous fistula, angioplasty, surveillance, outcome measure, access failure, procedure efficacy, predictive
measure
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Introduction
Vascular accesses (VAs) are considered to be the “Achilles
heel” of hemodialysis.1 Arteriovenous fistulas (AVFs) and
arteriovenous grafts (AVGs) are the preferred long-term
VA options for patients on hemodialysis. Access dysfunction is caused by “neointimal hyperplasia.”2,3 Stenosis is
the inward remodeling process of a vessel wall that produces luminal narrowing, which in turn affects blood flow
and intra-access pressures. VA surveillance leads to the
early identification of stenosis, providing sufficient lead
time for intervention before thrombosis.4 Surveillance
methods are mainly based on blood flow or intra-access
pressure.5,6 Invasive tests such as angiography are performed based on surveillance alerts combined with clinical
symptoms. Percutaneous transluminal balloon angioplasty
(PTA) is the initial therapy of choice in the management of
VA dysfunction.7 Selection of the angioplasty balloon size
and the residual stenosis estimation is operator dependent.
Residual stenosis <30% indicates a “successful” angioplasty procedure.
Despite improved technical success in treating stenosis, recurrence rates are very high, with only 40%–50%
of VAs maintaining patency without the need for subsequent procedures by 6 months.8 Angioplasty failure may
have disastrous consequences, requiring the use of endovascular stents or surgical revision and causing permanent access loss with intervening catheter use, thereby
increasing cost, morbidity, and mortality. Failure to
identify elastic recoil of treated stenosis and/or suboptimal treatment of the culprit lesion leads to persistence of
clinical symptoms, worsening of stenosis, and eventual
loss of patency. The actual frequency of delayed elastic
lesion is unknown and may be as high as 15%.9 This
recoil may at times be seen after the angioplasty when
performing repeat angiograms in 15-min intervals, but
this is not practical and does not identify lesions that
recoil more slowly.9 Existing surveillance methodologies fall short in monitoring VA in the immediate postprocedure period. A functional outcome measure
post-PTA would greatly help to identify accesses at
higher risk for failure, assist in assessing the quality of
the procedure, and might provide the lead time for the
next course of the intervention, potentially altering the
natural course of access dysfunction.
Functional effects of the angioplasty are not routinely
monitored.10 Distal radial artery pressure gradient, translesional pressure ratio, and catheter-based flow studies are
proposed to predict technical and patency outcomes in limited VA types and require additional resources.11–14 These
adjunctive methods are useful intraprocedure but have
limited applicability across various access types and clinical settings.
Vasc-AlertTM (Vasc-Alert, LLC, Lafayette, IN) is an
automated, noninvasive surveillance algorithm that monitors VA during every dialysis session.15 Dialysis machine
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data such as needle gauge, arterial and venous pressures,
blood flow, dialysis time, and patient hematocrit are electronically captured and uploaded to a cloud-based database system. A patented algorithm calculates the venous
intra-access pressure ratio (VAPR). The ratio is computed
by dividing the calculated VA pressure by the mean arterial
pressure (MAP). Vasc-Alert directly calculates the intraaccess pressure ratio of hemodialysis access at least six
times during each dialysis treatment. Pressure readings
are obtained with every dialysis session, are not timedependent, do not add material cost or additional staff
time, and do not interfere with dialysis delivery. Three
consecutive dialysis sessions with VAPRs that exceed the
threshold of 0.55 trigger an electronic alert sent to designated personnel in dialysis units. Patients with electronic
alert warnings in combination with clinical symptoms are
referred for PTA. A decrease in access pressure post-successful PTA should be noted as early as the next dialysis
session. The lack of this change after the PTA is likely due
to elastic recoil, underestimated balloon size, misidentification of the culprit lesion, or, less likely, an unrecognized
form of accelerated neointimal hyperplasia. The magnitude of pressure changes post-PTA is not explicit and
might depend on access type. We aimed to study the
degree of drop in VA pressure ratio after PTA to observe
whether post-PTA VAPR drop correlates with procedure
outcomes.

Materials and methods
We conducted a retrospective review of all patients of an
independent dialysis provider who were monitored using
the Vasc-Alert surveillance program and had a successful
PTA (alone or as part of successful thrombectomy).
Procedures were performed by different specialties at one
institution including interventional nephrology, vascular
surgery, and interventional radiology. Procedural success
was defined as <30% residual stenosis. The hospitalbased electronic medical record (EMR) (Epic, Epic
Systems Corp., Verona, WI) was used to identify patients
with end-stage renal disease (ESRD) who received a PTA
of VA from March 2014 to June 2016. Data collection
included demographics, comorbidities, VA type, location,
laterality, and access vintage (age of the access), mean of 3
VAPR values leading to the alert, mean of the first 3
VAPRs post-procedure, time-to-next intervention, years of
ESRD, site of stenosis, and access patency. The percent of
change (Δ%VAPR) derived from pre- and post-intervention VAPR was computed to measure the difference in the
intra-access pressure post-procedure. Subsequent access
failures were defined as undergoing access procedures or
permanent loss. The time to access failure at 3 months was
chosen for area under curve analysis, based on the Kidney
Disease Outcomes Quality Initiative (KDOQI) guideline
6.6 and North American Vascular Access Consortium
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Table 1. Baseline characteristics of the study population by the access type.
Variable

Response

Overall

Fistula

Graft

P-value

Age (years)
Dialysis vintage (years)
Access vintage (years)
Sex
Race

N; mean (SD)
N; mean (SD)
N; mean (SD)
Female
A
B
H
NA
W
Yes
Yes
Yes

138; 64.16 (12.23)
138; 6.00 (4.38)
138; 2.57 (62.05)
70 (50.7%)
3 (2.2%)
120 (87%)
1 (0.7%)
2 (1.4%)
12 (8.7%)
89 (64.5%)
125 (90.6%)
21 (15.2%)

64; 63.07 (11.98)
64; 4.28 (2.93)
64; 2.34 (1.96)
28 (43.8%)
2 (3.1%)
53 (82.8%)
1 (1.6%)
1 (1.6%)
7 (10.9%)
44 (68.8%)
59 (92.2%)
11 (17.2%)

74; 65.09 (12.45)
74; 7.49 (4.87)
74; 2.77 (2.28)
42 (56.8%)
1 (1.4%)
67 (90.5%)
0
1 (1.4%)
5 (6.8%)
45 (60.8%)
66 (89.2%)
10 (13.5%)

0.335
<0.001
0.222
0.128
0.46

DM
HTN
PAD

0.331
0.548
0.549

SD: standard deviation; A: Asian; B: Black; H: Hispanic; NA: unknown; W: White; DM: diabetes mellitus; HTN: hypertension; PAD: peripheral
arterial disease.

guidelines on standardized definitions for hemodialysis
VA months.16,17 The Institutional Review Board (IRB)
approved the study protocol with an exemption from
informed consent (IRB #9682).

Statistical methodology
All analyses were done using SAS version 9.4 (SAS
Institute, Inc., Cary, NC). A generalized estimating equation approach was used to model the repeated measures
per individual. The receiver operating characteristic
(ROC) curve was generated as a plot of sensitivity versus 1-specificity where the screening characteristics
were produced for each possible cut-point (change in
VAPR; Δ%). An optimal cut-point was designed as the
value that maximized the sum of sensitivity and specificity which treats false-positive and false-negative values
as equally important in deciding a cut-point. Follow-up
analyses assessed how well the best cut-point predicted
survival using a cluster data approach to both the
Kaplan–Meier estimate and a multivariate Cox model
using the robust sandwich covariance matrix estimate
which evaluates the effect of Δ%VAPR adjusting for significant covariates.

Results
Over a 27-month period, PTA was performed in 138 subjects (Black 87%, diabetes mellitus 65%, hypertension
91%, and peripheral arterial disease 15%) that included 64
AVFs with 104 angioplasties (1.63 angioplasties/access)
and 74 AVGs with 134 angioplasties (1.81 angioplasties/
access) (Table 1). Two-thirds of AVF angioplasties were in
brachiocephalic fistula (n = 66, 67%) while AVG angioplasties were predominantly of C-shape configuration
(n = 54, 63%). Only one procedure had a stent placement
along with angioplasty. High-pressure angioplasty balloons were employed in 49 procedures. Patients with AVF

(44% women) had a mean age of 63.1 years, a mean of
4.3 years on dialysis, and an access vintage of 2.3 years.
Patients with AVG (57% women) had a mean age of
65 years with a mean of 7.5 years on dialysis and an access
vintage of 2.8 years. Solitary stenosis was noted in 67% of
procedures. Stenosis distribution (solitary or in combination with other sites) was predominantly in downstream
direction (cephalic arch: n = 40, swing segment: n = 18,
vein graft anastomosis: n = 105, intra-stent lesions: n = 9,
central veins: n = 14, intra-access: n = 87). There were no
significant associations between site of stenosis and
Δ%VAPR in both AVF and AVG. There were no significant differences in the prevalence of diabetes, hypertension, peripheral arterial disease, use of high-pressure PTA
balloon, or the number of angioplasties per access except
for the AVG group, which had a longer dialysis vintage
compared to the AVF group (7.5 vs 4.3 years, P < 0.001).
The area under the ROC curve for access failure
(AVF + AVG) at 3 months was 0.569, with an optimal cutoff value of 31.2%, sensitivity of 54.6%, and specificity of
63.1%. Access with a <31.2% drop had a 62% increase in
the risk of failure (hazard ratio (HR) 1.62; 95% confidence
interval (CI) 1.16, 2.27; P = 0.005). The distribution of the
Δ%VAPR variable was not normally distributed, as noted
with the Shapiro–Wilk test (P < 0.001), and had several
large outliers. Of 238 observations, 38 (18 AVF and 20
AVG) had a directional increase in the post-procedure
venous intra-access pressure ratio test (VAPRT). Of these
38 observations, 13 in the AVF group and 12 in the AVG
group failed by 3 months. Compared to the accesses with a
change of 0%–31%, the directional increase in post-procedure VAPRT did not enhance the risk of access failure
(P = 0.43).

Predictive value of Δ%VAPR in AVF
Among the 104 procedures in the fistula group, the mean
post-procedure change in VAPR (Δ%) was 32.5 ± 36.1
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(standard deviation (SD)). The area under the ROC curve
for fistula failure at 3 months was 0.59, with an optimal
cut-point of 33.3%, a sensitivity of 56.1%, and a specificity of 63.2% (Figure 1). Generalized estimating equation
survival analysis for time to fistula failure is shown in
Figure 2, with lower survival rates for fistula with
<33.3% drop post-angioplasty. Table 2 provides adjusted
HRs and 95% CIs from a multivariable Cox proportional
hazards model, modeled with multiple time-points per
individual as clusters modeling time to fistula failure.
Each effect is interpreted as the effect while controlling
for all other variables presented in the model. Nearly half
of AVFs (n = 51) had a <33.3% drop in VAPR post-PTA.
Fistula with <33.3% drop had a 99% increase in the risk
of failure (HR 1.99 (CI 1.14, 3.89), P = 0.016) with a
lower median survival of AVF (136 vs 231 days, P = 0.01).
There was no evidence that the other variables in the
multivariable model had unique associations with time to
fistula failure.

Predictive value of Δ%VAPR in AVG
Figure 1. ROC curve for percent delta VAPR for fistulas,
predicting failure at 3 months.

In the ROC curve, sensitivity is on the vertical axis and 1-specificity on
the horizontal axis.

Among the 134 procedures in the AVG group, the mean
post-procedure change in Δ%VAPR was 32.3 ± 33.6 SD.
The area under the ROC curve for graft failure at 3 months

Figure 2. Kaplan–Meier survival curve estimates for time to fistula failure, stratified by percent delta VAPR dichotomized at 33.3.
Access survival was significantly better for AVF with >33.3% drop in VAPR post-angioplasty than AVF with <33.3% drop in VAPR
(log-rank test, P = 0.007).
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Table 2. Summary of multivariable Cox regression analysis for
time to fistula failure.
Variables

HR (95% CI)

P-value

Δ%VAPR < 33.3%
Male
Age
Access vintage
Diabetes mellitus

2.06 (1.19, 3.57)
0.64 (0.34, 1.18)
1.00 (0.97, 1.02)
0.91 (0.77, 1.08)
1.32 (0.73, 2.40)

0.010
0.15
0.849
0.302
0.361

HR: hazard ratio; CI: confidence interval; VAPR: venous access pressure ratio.

Figure 3. ROC curve for percent delta VAPR (Δ%) for grafts,
predicting failure at 3 months.

In the ROC curve, Δ% levels are plotted for their ability to predict
graft failure at 3 months with sensitivity on the vertical axis and 1-specificity on the horizontal axis.

was 0.55, with a cut-point of 28.8% giving a sensitivity of
52.3% and specificity of 67.4% (Figure 3). A generalized
estimation equation analysis for time to graft failure is
shown in Figure 4 with a lower survival for the graft with
a <28.8% decline. Table 3 provides adjusted HRs and
95% CIs from a multivariable Cox proportional hazards
model for clustered data, modeling time-to-graft failure.
Exactly 46% AVG (n = 61) had a <28.8% drop in VAPR
post-PTA. Graft, which had a <28.8% drop in VAPR
within the first week post-angioplasty, had a 59% higher
risk of failure (HR 1.59 (CI 1.07, 2.36), P = 0.02) with
lower median survival (144 vs 189 days, P = 0.04). There
was no evidence that the other variables, including age of
access in the multivariable model, had unique associations
with time-to-graft failure.

Discussion
This study evaluated the interval change in pressure of
AVFs and AVGs after the PTA to assess outcome and survivability. The principal finding of this study indicates that
PTA post-pressure changes can predict subsequent access
patency and survival. We report automated VA pressurebased predictive measures to evaluate post-procedure
outcomes.
Post-PTA residual stenosis is frequently used to
express the efficiency of PTA procedures. Outcomes of
access dysfunction treated predominantly with PTA are
influenced by accuracy in the identification of the culprit
stenosis and the use of appropriate balloon type and size.
The quantification of stenosis18 and the choice of the balloon are operator-dependent with inventory limitations.
Treated stenosis has the potential to recoil or recur in a
short time after the procedure. Unlike access blood flow,
post-PTA fluoroscopic changes are not shown to be predictors of functional outcome measures. Delayed elastic
recoil is a frequent finding post-angioplasty with a prevalence as high as 10% at 5 min after a technically successful angioplasty.9 Elastic recoil has not been shown to
influence access survivability but still is used as an
indication for implantation of endovascular stents
emphasizing further the need for functional markers.9
Notwithstanding these limitations, the lack of alternative
measures has led to angiographic imaging being the principal marker of procedural efficiency. Considering that
elastic recoil does not have any influence on access survivability, the effect of the VAPRT changes within the
first week after PTA in our study likely indicates procedural efficiency.
In our study, we demonstrated that the changes in
pressure profiles post-PTA could be used to predict
access outcomes. Identifying a single methodology as an
outcome measure in two biologically different access
types with a diverse natural course but with a common
etiology for dysfunction is a significant challenge. The
combined access analysis provides a cut-point of a 31.2%
drop as a single predictive measure. The lack of adequate
pressure improvement post PTA could either be due to
suboptimal interventions or the biological nature of the
stenosis. The Δ%VAPR provides a single, clinically relevant, pragmatic, and objective measure assessing
responses to PTA in fistulas and grafts.
Objective parameters reported in the literature to date
can be broadly classified into flow-based and pressurebased measures.19,20 Intraprocedure pressure–based settings are meant to identify hemodynamically significant
stenosis missed by angiography. Asif et al.10 described the
intra-access static pressure ratio measured during
angioplasty for 70 AVGs, demonstrating a decline of 38%
post-intervention and nearly doubling the access flow at
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Figure 4. Kaplan–Meier survival curve estimates for time to graft failure, stratified by percent delta VAPR dichotomized at 28.8.
Access survival was significantly better for AVG with >28.8% drop in VAPR post-angioplasty than AVG with <28.8% drop in VAPR
(log-rank test, P = 0.046).
Table 3. Summary of multivariable Cox regression analysis for
time to graft failure.
Variables

HR (95% CI)

P-value

Δ%VAPR < 28.8%
Male
Age
Access vintage
Diabetes mellitus

1.54 (1.03, 2.31)
0.63 (0.34, 1.17)
0.99 (0.97, 1.01)
1.02 (0.91, 1.15)
1.33 (0.81, 2.27)

0.036
0.146
0.388
0.700
0.252

HR: hazard ratio; CI: confidence interval; VAPR: venous access pressure
ratio.

2 weeks. Funaki et al.21 described trans-stenotic pressure
gradient post-PTA as an intraprocedural adjunct to angiography to evaluate the results of PTA in grafts. Lin et al.12
determined the trans-stenotic gradient across central
venous stenosis angioplasty to be better than residual stenosis. Lai et al.22 reported intra-graft pressure (IGP) as an
intraprocedural objective measure for angioplasty of
AVG. Pre-PTA IGP and post-PTA IGP were shown to be
predictive of 1-year patency. The study also had nearly
60% procedure failure and residual stenosis of >60%
reinforcing angiography`s weakness as a marker of efficiency. Lai et al.11 also reported distal radial artery
pressure measured at the time of procedure as a marker
of angiographic outcomes and 3-month primary access

patency. Reported studies to date are limited to intraprocedural measurements that require additional resources,
adds to procedure times, cost, and specific access types.
Although our study does not provide intraprocedural
information, it includes information accrued in the postprocedural period without adding further cost and is
applicable to both access types and practical in a community setting.
Access flow (AF) measurements using ultrasound dilution or ionic dialysance have been well studied and widely
used for access surveillance.23,24 The effect of preemptive
angioplasty on AF has been reported with mixed results.
Post-angioplasty AF in AVG has been reported to nearly
double from pre-procedure levels in the first month with
subsequent progressive decline to reach pre-intervention
levels by the third month.25 In a study of 28 AVGs, almost
15% had thrombosed and were lost in the third month.
AVGs that achieve less than 1 L/min of AF post-intervention tend to have higher failures by 6 months, and lower
1-year assisted patency.26 Similar results have been
reported by Van der Linden et al.27 and Tessitore et al.28
Post-intervention AF measurement using the delta H
method was proposed for functional surveillance by
Roca-Tey et al.29 The significant hurdles in using AF as an
efficiency marker are its inherent weaknesses. AF measurements are time dependent and vary during and between
dialysis sessions. The study conducted by Polkinghorne
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et al.30 measured AF multiple times during the dialysis
session for three consecutive sessions. Significant reductions in flow and MAP were progressively noted throughout the dialysis treatment. AF may decrease by 10%–30%
during the last hour of dialysis.30 Similar results were
found by Huisman et al.31 using a duplex Doppler ultrasound and Doppler ultrasound study methods. AFs are
performed monthly. Frequent measurements of AF are
cost-prohibitive, affect dialysis delivery, and remain
impractical. Routine use of AF as a marker of procedural
or access efficiency can be questionable at best.
Our study addresses many of these limitations of AF.
Access pressure measurements are obtained during every
dialysis session, are not time dependent, do not add cost,
and do not interfere with dialysis delivery. Both delayed
elastic recoil and suboptimal procedures can be accounted
for in real-time automated settings using the mean VAPR
of the first three sessions after intervention. The additional
time obtained by our outcome measure could be utilized in
planning salvage procedures or new access placement,
avoiding interim catheter use.
The role of surveillance is still controversial,32 and our
study has several limitations inherent to any retrospective
design. However, a definite signal can be detected for
increased hazards from a lack of adequate change in intraaccess pressure following PTA. A blinded interventionist
review of the images for stenosis identification and severity was not performed, limiting analyses that compare
pressure changes with residual stenosis. The external validation of this predictive model development dataset in a
different practice pattern with varied demographic compositions would be needed. Low sensitivity and moderate
specificity impede its utility as a diagnostic test. The flat
area under the curve is most likely due to the skewed distribution of Δ%VAPR, as noted by the Shapiro–Wilkes
test. The low specificity of Δ%VAPR is expected due to
co-existence of more than one stenosis segment, and combining it with post-intervention clinical symptoms might
improve its specificity. Our study also lacks an intraprocedural pressure profile and is unable to ascertain if the failure of VAPR decline was due to an intraprocedure or
post-procedure event. Our study does not address the
impact of endovascular stent placement and its effect on
the pressure profile, as only one angioplasty with stent
placement was included. The study does not discuss pressure changes in subsequent procedural outcomes in the
same access. Our review also does not examine the effect
of time from alert to procedure and its impact on the
response. Despite limitations, our study provides a valuable prognostic parameter useful for assessing post-procedure access outcomes.

Conclusion
We report for the first time an electronic VA pressure-based
outcome measure that can evaluate procedure efficacy and

access outcomes. This simple tool can identify access failure earlier than traditional symptoms of VA dysfunction
and can aid in developing value-based procedure outcome
measures and/or identifying failing access. Prospective
studies evaluating the incorporation of Δ%VAPR in access
surveillance, its impact on access survival, and cost-benefit analysis are needed.
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